Sustained release of antiinfectives

Abstract

Provided, among other things, is a method of treating or ameliorating pulmonary infection in a cystic fibrosis patient comprising pulmonary administration of an effective amount of a liposomal/complexed antiinfective to the patient, wherein the (i) administrated amount is 50% or less of the comparative free drug amount, or (ii) the dosing is once a day or less, or (iii) both.

1 .- 11 . (canceled) 
     
     
         12 . A liposomal ciprofloxacin formulation comprising ciprofloxacin encapsulated in liposomes, wherein the lipid component of the liposomes comprises cholesterol and hydrogenated soy phosphatidylcholine (HSPC), and the lipid component to ciprofloxacin weight ratio is less than 2.5:1 by weight, wherein the liposomes are unilamellar. 
     
     
         13 . A method of treating a  Pseudomonas aeruginosa  infection or an infection due to  P. aeruginosa  in the lungs of a patient in need thereof, comprising administering to the lungs of the patient an effective amount of a liposomal ciprofloxacin formulation comprising ciprofloxacin encapsulated in liposomes, wherein the lipid component of the liposomes comprises cholesterol and hydrogenated soy phosphatidylcholine (HSPC), and the lipid component to ciprofloxacin weight ratio is less than 2.5:1 by weight, wherein the liposomes are unilamellar. 
     
     
         14 . The method of  claim 13 , wherein the formulation is administered via inhalation. 
     
     
         15 . The method of  claim 14 , wherein the formulation is administered as an aerosol.